Additional information
NA
1148113-53-4
ACI-011611
C23H21F7N4O3
534.43
Ambient
2-8°C
Anticancer
Pharmaceutical Impurity Standards
5-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one
(3-[[(2R,3R)-2-[(R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholino]methyl]-1H-1,2,4-triazol-5(4H)-one))
Aprepitant Related Compound A; Aprepitant EP Impurity E;(R,R,R)-Aprepitant





![6,9-DIACYL PACLITAXEL (25 mg) ((2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-Acetoxy-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,9-diyl (2R,2'R,3S,3'S)-bis(3-benzamido-2-hydroxy-3-phenylpropanoate))](https://analyticachemie.in/ver-2/wp-content/uploads/uspimage-1.jpg)